Brief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
21/10/2026 13:31
BRIEF-Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027 Oct 21 (Reuters) - Voyager Therapeutics, Inc. VYGR.O:
VOYAGER ANNOUNCES CEO SUCCESSION PLAN, APPOINTS ROBIN SWARTZ PRESIDENT
APPOINTS ROBIN SWARTZ AS PRESIDENT; EXPECTED TO SUCCEED AS CEO IN Q1 2027
DR. SANDROCK TO REMAIN CEO THROUGH Q1 2027; WILL CONTINUE AS BOARD MEMBER
ROBIN SWARTZ EXPECTED TO SUCCEED AS CEO IN Q1 2027 AFTER VY1706 SAFETY DATA
Source text: ID:nGNX9s0hnl
Further company coverage: VYGR.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview